Neuromod Devices is a global medical technology company founded to establish bimodal neuromodulation as a new standard of care for tinnitus, a condition that affects 15% of the global adult population.
The culmination of Neuromod’s research and development in this area for over a decade is the groundbreaking bimodal neuromodulation tinnitus treatment device, Lenire®.
Neuromod has clinically proven the safety, efficacy and patient tolerability of Lenire through three large-scale clinical trials involving 600+ tinnitus patients and real-world evidence. Lenire research has been published in prestigious peer-reviewed scientific journals.
This technology is protected by the largest and earliest IP portfolio in bimodal neuromodulation for tinnitus with 134 global patents across 37 countries.
Neuromod’s comprehensive and consistent body of clinical trial and real world evidence saw Lenire® become the first device of its kind to be awarded an FDA De Novo Grant for the treatment of tinnitus in the United States of America.